Article

Tyrosine Kinase ALK/LTK Inhibitors Target B Lymphocytes

2023-02-24

Abstract excerpt

Autoimmune disorders and some types of blood cancer originate when B lymphocytes malfunction. In particular, when B cells produce antibodies recognizing the body’s proteins, it leads to various autoimmune disorders. And when B cells of various developmental stages transform into cancer cells, it results in blood cancers, including multiple myeloma, lymphoma, and leukemia. Thus, new methods of targeting B cel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8ce30a1e-cafc-5ec8-8299-cc969bdfbaa3
DOI: 10.20944/preprints202302.0423.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Tyrosine Kinase ALK/LTK Inhibitors Target B LymphocytesDOI 10.20944/preprints202302.0423.v1Read

Tyrosine kinase inhibitors target B cellsSemantic proximity Read

Targeting BMI-1 to deplete antibody-secreting cells in autoimmunitySemantic proximity Read

Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?Semantic proximity Read

Investigation of novel therapeutic strategies in B cell and antibody mediated diseaseSemantic proximity Read

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.Semantic proximity Read

Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Semantic proximity Read

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read

CD4⁺ T-cell reserve predicts bispecific antibody efficacy and can be enhanced by BTK inhibition in B-cell lymphomaSemantic proximity Read